Do analysts recommend VERO or LYRA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Venus Concept 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lyra Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Do analysts prefer VERO or PFSA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Venus Concept 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Profusa 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is VERO or PFSA more profitable?

Profusa has a net margin of 0.00% compared to Venus Concept's net margin of -92.76%. Profusa's return on equity of 0.00% beat Venus Concept's return on equity. Company Net Margins Return on Equity Return on Assets Venus Concept -92.76% -1,904.25% -85.22% Profusa N/A N/A -1,348.07%

Do analysts rate SSKN or VERO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Strata Skin Sciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Venus Concept 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer VERO or DYNT?

Given Dynatronics' higher probable upside, analysts plainly believe Dynatronics is more favorable than Venus Concept. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Venus Concept 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Dynatronics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is VERO or DYNT more profitable?

Dynatronics has a net margin of -8.35% compared to Venus Concept's net margin of -92.76%. Dynatronics' return on equity of -41.81% beat Venus Concept's return on equity. Company Net Margins Return on Equity Return on Assets Venus Concept -92.76% -1,904.25% -85.22% Dynatronics -8.35% -41.81% -9.56%

Do analysts prefer BIOL or VERO?

Given BIOLASE's higher possible upside, research analysts plainly believe BIOLASE is more favorable than Venus Concept. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BIOLASE 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Venus Concept 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is BIOL or VERO more profitable?

BIOLASE has a net margin of -41.65% compared to Venus Concept's net margin of -92.76%. BIOLASE's return on equity of -1,782.73% beat Venus Concept's return on equity. Company Net Margins Return on Equity Return on Assets BIOLASE -41.65% -1,782.73% -55.31% Venus Concept -92.76% -1,904.25% -85.22%

Venus Concept (VERO) Competitors

$0.31 0.00 (0.00%)

As of 06/18/2026

Compare

VERO vs. LYRA, PFSA, SSKN, DYNT, and BIOL

Should you buy Venus Concept stock or one of its competitors? MarketBeat compares Venus Concept with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Venus Concept include Lyra Therapeutics (LYRA), Profusa (PFSA), Strata Skin Sciences (SSKN), Dynatronics (DYNT), and BIOLASE (BIOL). These companies are all part of the "medical equipment" industry.

How does Venus Concept compare to Lyra Therapeutics?

Venus Concept (NASDAQ:VERO) and Lyra Therapeutics (NASDAQ:LYRA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment and analyst recommendations.

Venus Concept has a net margin of -92.76% compared to Lyra Therapeutics' net margin of -5,491.17%. Lyra Therapeutics' return on equity of -1,010.91% beat Venus Concept's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Venus Concept	-92.76%	-1,904.25%	-85.22%
Lyra Therapeutics	-5,491.17%	-1,010.91%	-58.92%

Venus Concept has a beta of -0.06, suggesting that its share price is 106% less volatile than the broader market. Comparatively, Lyra Therapeutics has a beta of 0.7, suggesting that its share price is 30% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Venus Concept	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lyra Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

In the previous week, Lyra Therapeutics had 1 more articles in the media than Venus Concept. MarketBeat recorded 1 mentions for Lyra Therapeutics and 0 mentions for Venus Concept. Lyra Therapeutics' average media sentiment score of 0.67 beat Venus Concept's score of 0.00 indicating that Lyra Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Venus Concept	Neutral
Lyra Therapeutics	Positive

87.4% of Venus Concept shares are owned by institutional investors. Comparatively, 95.6% of Lyra Therapeutics shares are owned by institutional investors. 28.0% of Venus Concept shares are owned by company insiders. Comparatively, 3.3% of Lyra Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Venus Concept has higher revenue and earnings than Lyra Therapeutics. Lyra Therapeutics is trading at a lower price-to-earnings ratio than Venus Concept, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Venus Concept	$58.88M	0.01	-$47M	-$48.84	N/A
Lyra Therapeutics	$600K	2.01	-$93.43M	-$19.15	N/A

Summary

Lyra Therapeutics beats Venus Concept on 9 of the 14 factors compared between the two stocks.

How does Venus Concept compare to Profusa?

Venus Concept (NASDAQ:VERO) and Profusa (NASDAQ:PFSA) are both small-cap medical equipment companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, risk, profitability, media sentiment and institutional ownership.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Venus Concept	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Profusa	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Venus Concept's average media sentiment score of 0.00 equaled Profusa'saverage media sentiment score.

Company	Overall Sentiment
Venus Concept	Neutral
Profusa	Neutral

Profusa has a net margin of 0.00% compared to Venus Concept's net margin of -92.76%. Profusa's return on equity of 0.00% beat Venus Concept's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Venus Concept	-92.76%	-1,904.25%	-85.22%
Profusa	N/A	N/A	-1,348.07%

87.4% of Venus Concept shares are owned by institutional investors. Comparatively, 9.8% of Profusa shares are owned by institutional investors. 28.0% of Venus Concept shares are owned by company insiders. Comparatively, 0.8% of Profusa shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profusa has lower revenue, but higher earnings than Venus Concept. Venus Concept is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Venus Concept	$58.88M	0.01	-$47M	-$48.84	N/A
Profusa	$100K	8.39	-$35.82M	-$169.72	N/A

Venus Concept has a beta of -0.06, meaning that its share price is 106% less volatile than the broader market. Comparatively, Profusa has a beta of 0.35, meaning that its share price is 65% less volatile than the broader market.

Summary

Profusa beats Venus Concept on 6 of the 11 factors compared between the two stocks.

How does Venus Concept compare to Strata Skin Sciences?

Strata Skin Sciences (NASDAQ:SSKN) and Venus Concept (NASDAQ:VERO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Strata Skin Sciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Venus Concept	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Strata Skin Sciences had 1 more articles in the media than Venus Concept. MarketBeat recorded 1 mentions for Strata Skin Sciences and 0 mentions for Venus Concept. Strata Skin Sciences' average media sentiment score of 0.00 equaled Venus Concept'saverage media sentiment score.

Company	Overall Sentiment
Strata Skin Sciences	Neutral
Venus Concept	Neutral

Strata Skin Sciences has a net margin of -35.64% compared to Venus Concept's net margin of -92.76%. Strata Skin Sciences' return on equity of -476.73% beat Venus Concept's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Strata Skin Sciences	-35.64%	-476.73%	-33.49%
Venus Concept	-92.76%	-1,904.25%	-85.22%

32.4% of Strata Skin Sciences shares are owned by institutional investors. Comparatively, 87.4% of Venus Concept shares are owned by institutional investors. 40.9% of Strata Skin Sciences shares are owned by insiders. Comparatively, 28.0% of Venus Concept shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Strata Skin Sciences has higher earnings, but lower revenue than Venus Concept. Strata Skin Sciences is trading at a lower price-to-earnings ratio than Venus Concept, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Strata Skin Sciences	$30.98M	0.03	-$10.09M	-$1.41	N/A
Venus Concept	$58.88M	0.01	-$47M	-$48.84	N/A

Strata Skin Sciences has a beta of -0.06, indicating that its share price is 106% less volatile than the broader market. Comparatively, Venus Concept has a beta of -0.06, indicating that its share price is 106% less volatile than the broader market.

Summary

Strata Skin Sciences beats Venus Concept on 8 of the 11 factors compared between the two stocks.

How does Venus Concept compare to Dynatronics?

Venus Concept (NASDAQ:VERO) and Dynatronics (NASDAQ:DYNT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and earnings.

In the previous week, Venus Concept's average media sentiment score of 0.00 equaled Dynatronics'average media sentiment score.

Company	Overall Sentiment
Venus Concept	Neutral
Dynatronics	Neutral

Venus Concept has a beta of -0.06, suggesting that its share price is 106% less volatile than the broader market. Comparatively, Dynatronics has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market.

87.4% of Venus Concept shares are held by institutional investors. Comparatively, 4.2% of Dynatronics shares are held by institutional investors. 28.0% of Venus Concept shares are held by company insiders. Comparatively, 2.9% of Dynatronics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Dynatronics has a net margin of -8.35% compared to Venus Concept's net margin of -92.76%. Dynatronics' return on equity of -41.81% beat Venus Concept's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Venus Concept	-92.76%	-1,904.25%	-85.22%
Dynatronics	-8.35%	-41.81%	-9.56%

Dynatronics has lower revenue, but higher earnings than Venus Concept. Venus Concept is trading at a lower price-to-earnings ratio than Dynatronics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Venus Concept	$58.88M	0.01	-$47M	-$48.84	N/A
Dynatronics	$33.60M	0.00	-$2.70M	-$1.35	N/A

Given Dynatronics' higher probable upside, analysts plainly believe Dynatronics is more favorable than Venus Concept.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Venus Concept	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Dynatronics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Dynatronics beats Venus Concept on 7 of the 12 factors compared between the two stocks.

How does Venus Concept compare to BIOLASE?

BIOLASE (NASDAQ:BIOL) and Venus Concept (NASDAQ:VERO) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, institutional ownership, media sentiment, risk, dividends, analyst recommendations, profitability and earnings.

BIOLASE has higher earnings, but lower revenue than Venus Concept. Venus Concept is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BIOLASE	$48.83M	0.00	-$20.63M	-$14.94	N/A
Venus Concept	$58.88M	0.01	-$47M	-$48.84	N/A

In the previous week, BIOLASE's average media sentiment score of 0.00 equaled Venus Concept'saverage media sentiment score.

Company	Overall Sentiment
BIOLASE	Neutral
Venus Concept	Neutral

8.8% of BIOLASE shares are held by institutional investors. Comparatively, 87.4% of Venus Concept shares are held by institutional investors. 0.3% of BIOLASE shares are held by company insiders. Comparatively, 28.0% of Venus Concept shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Given BIOLASE's higher possible upside, research analysts plainly believe BIOLASE is more favorable than Venus Concept.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BIOLASE	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Venus Concept	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

BIOLASE has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market. Comparatively, Venus Concept has a beta of -0.06, meaning that its stock price is 106% less volatile than the broader market.

BIOLASE has a net margin of -41.65% compared to Venus Concept's net margin of -92.76%. BIOLASE's return on equity of -1,782.73% beat Venus Concept's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BIOLASE	-41.65%	-1,782.73%	-55.31%
Venus Concept	-92.76%	-1,904.25%	-85.22%

Summary

BIOLASE beats Venus Concept on 8 of the 12 factors compared between the two stocks.

Get Venus Concept News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VERO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VERO vs. The Competition

Export

Metric	Venus Concept	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$442K	$7.11B	$6.65B	$12.60B
Dividend Yield	N/A	1.25%	2.68%	5.81%
P/E Ratio	-0.01	47.59	24.75	24.42
Price / Sales	0.01	75.62	529.30	111.09
Price / Cash	N/A	25.66	27.92	37.84
Price / Book	0.07	7.26	10.81	6.60
Net Income	-$47M	$159.20M	$3.57B	$337.10M
7 Day Performance	N/A	-0.49%	0.72%	0.83%
1 Month Performance	N/A	1.29%	0.41%	2.25%
1 Year Performance	-86.01%	7.51%	29.34%	36.14%

Venus Concept Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VERO Venus Concept	N/A	$0.31 flat	N/A	N/A	$442K	$58.88M	N/A	410
LYRA Lyra Therapeutics	0.5847 of 5 stars	$0.69 +6.2%	N/A	-93.5%	$1.23M	$600K	N/A	50	Gap Down
PFSA Profusa	0.076 of 5 stars	$0.22 -6.9%	N/A	N/A	$1.10M	$100K	N/A	2	High Trading Volume
SSKN Strata Skin Sciences	0.1228 of 5 stars	$0.15 +23.1%	N/A	-94.1%	$877K	$30.98M	N/A	120	Gap Up
DYNT Dynatronics	N/A	N/A	N/A	N/A	$653K	$33.60M	N/A	200

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VERO) was last updated on 6/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Venus Concept (VERO) Competitors

VERO vs. LYRA, PFSA, SSKN, DYNT, and BIOL

How does Venus Concept compare to Lyra Therapeutics?

Summary

How does Venus Concept compare to Profusa?

Summary

How does Venus Concept compare to Strata Skin Sciences?

Summary

How does Venus Concept compare to Dynatronics?

Summary

How does Venus Concept compare to BIOLASE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VERO vs. The Competition

Venus Concept Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Venus Concept (VERO) Competitors

VERO vs. LYRA, PFSA, SSKN, DYNT, and BIOL

How does Venus Concept compare to Lyra Therapeutics?

Is VERO or LYRA more profitable?

Which has more volatility & risk, VERO or LYRA?

Do analysts recommend VERO or LYRA?

Does the media prefer VERO or LYRA?

Do insiders & institutionals have more ownership in VERO or LYRA?

Which has better valuation & earnings, VERO or LYRA?

Summary

How does Venus Concept compare to Profusa?

Do analysts prefer VERO or PFSA?

Does the media favor VERO or PFSA?

Is VERO or PFSA more profitable?

Do insiders and institutionals hold more shares of VERO or PFSA?

Which has better valuation and earnings, VERO or PFSA?

Which has more volatility & risk, VERO or PFSA?

Summary

How does Venus Concept compare to Strata Skin Sciences?

Do analysts rate SSKN or VERO?

Does the media favor SSKN or VERO?

Is SSKN or VERO more profitable?

Do insiders and institutionals have more ownership in SSKN or VERO?

Which has higher valuation and earnings, SSKN or VERO?

Which has more risk & volatility, SSKN or VERO?

Summary

How does Venus Concept compare to Dynatronics?

Does the media favor VERO or DYNT?

Which has more risk & volatility, VERO or DYNT?

Do insiders & institutionals have more ownership in VERO or DYNT?

Is VERO or DYNT more profitable?

Which has higher earnings and valuation, VERO or DYNT?

Do analysts prefer VERO or DYNT?

Summary

How does Venus Concept compare to BIOLASE?

Which has better earnings & valuation, BIOL or VERO?

Does the media refer more to BIOL or VERO?

Do institutionals and insiders hold more shares of BIOL or VERO?

Do analysts prefer BIOL or VERO?

Which has more volatility & risk, BIOL or VERO?

Is BIOL or VERO more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VERO vs. The Competition

Venus Concept Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools